The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
Open accessAbstract
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractory patients. Here we report phase II studies using a similar material (FCE28068) in patients with breast (n=17), non-small cell lung (NSCLC, n=29) and colorectal (n=16) cancer. Up to 8 courses of PK1 (280 mg/m(2) doxorubicin-equivalent) were given i.v., together with 123I-labelled imaging analogue. Toxicities were tolerable, with grade 3 neutropenia more prominent in patients with breast cancer (4/17, 23.5% compared with 5/62, 8.1% overall). Of 14 evaluable patients with breast cancer 3 had partial responses (PR), all anthracycline-naïve patients. In 26 evaluable patients with NSCLC, 3 chemotherapy-naïve patients had PR. In contrast, none of the 16 evaluable patients with colorectal cancer responded. Imaging of 16 patients (5 with breast cancer, 6 NSCLC, 5 colorectal cancer) showed obvious tumour accumulation in 2 metastatic breast cancers, although unfortunately no images were obtained from patients who responded. These results show 6/62 PR with limited side effects, supporting the concept that polymer-bound therapeutics can have modified and improved anticancer activities and suggesting the approach should be explored further for breast cancer and NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Saito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo
Maeda, H., Seymour, L. W., & Miyamoto, Y. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00017a001 · Cited by 560
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., & Gabizon, A. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z · Cited by 385
Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour, L. W. (1992) · PubMed · Cited by 316
Meerum Terwogt, J. M., ten Bokkel Huinink, W. W., Schellens, J. H., Schot, M., Mandjes, I. A., Zurlo, M. G., Rocchetti, M., Rosing, H., Koopman, F. J., & Beijnen, J. H. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200104000-00003 · Cited by 279
Duncan, R. (1999) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(99)00211-4 · Cited by 192
Preclinical evaluation of polymer-bound doxorubicin
Duncan, R., Seymour, L. W., O'Hare, K. B., Flanagan, P. A., Wedge, S., Hume, I. C., Ulbrich, K., Strohalm, J., Subr, V., Spreafico, F., et al. (1992) · Journal of Controlled Release · doi:10.1016/0168-3659(92)90088-9 · Cited by 187
Julyan, P. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00124-2 · Cited by 180
Seymour, L., Ulbrich, K., Steyger, P., Brereton, M., Subr, V, Strohalm, J., & Duncan, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.363 · Cited by 164
Antibody-targeted Polymer–doxorubicin Conjugates with pH-controlled Activation
Ulbrich, K., Etrych, T., Chytil, P., Jelínková, M., & Řı́hová, B. (2004) · Journal of drug targeting · doi:10.1080/10611860400011869 · Cited by 128
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
Schoemaker, N. E., van Kesteren, C., Rosing, H., Jansen, S., Swart, M., Lieverst, J. A., Fraier, D., Breda, M., Pellizzoni, C., Spinelli, R., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600516 · Cited by 122
Cummings, J., & McArdle, C. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.141 · Cited by 109
Jones, A. T., Gumbleton, M., & Duncan, R. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.07.002 · Cited by 96
Thomson, A. H., Vasey, P. A., Murray, L. S., Cassidy, J., Fraier, D., Frigerio, E., & Twelves, C. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690657 · Cited by 81
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin
Conley, B. A., Egorin, M. J., Whitacre, M. Y., Carter, D. C., Zuhowski, E. G., & Echo, D. A. V. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685327 · Cited by 50
Polymer-protein and polymer-drug conjugates in cancer therapy.
Thanou, M., & Duncan, R. (2003) · PubMed · Cited by 50
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors
Veronese, M. L., Flaherty, K. T., Kramer, A., Konkle, B. A., Morgan, M. A., Stevenson, J. P., & O'Dwyer, P. J. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0938-3 · Cited by 31
Richly, H., Kupsch, P., Passage, K. J., Grubert, M., Hilger, R. A., Kredtke, S., Voliotis, D., Scheulen, M. E., Seeber, S., & Strumberg, D. (2003) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp41620 · Cited by 28
HPMA Copolymer-1,5-Diazaanthraquinone Conjugates as Novel Anticancer Therapeutics
Vicent, M. J., Manzanaro, S., de la Fuente, J. Á., & Duncan, R. (2004) · Journal of drug targeting · doi:10.1080/10611860400011901 · Cited by 23
Cited by
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,257
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Metadata
- Authors
- Seymour
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2009-05-07
- Volume
- 34
- Issue
- 6
- Pages
- 1629-36
- ISSN
- 1019-6439 (ISSN-L)
- OpenAlex
- W2148649439
- Cited by
- 304
- References
- 24
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.